We reviewed the CDA 2013 guidelines on antihyperglycemic therapy for type 2 diabetes (http://guidelines.diabetes.ca/executivesummary/ch13), and explored the pharmacological properties of each of the major classes: Biguanides: Metformin Sulfonylureas: 

To round up the "Big Three", we turned out attention on diabetes. We reviewed the CDA guidelines on diabetes management and summarized the most relevant points that we think all family doctors and pharmacists would find interesting. http://guidelines.dia

In this episode, we listed the life-style management of dyslipidemia and lowering cardiovascular disease risk, and dived into the main classes of medications for lipid lowering: statins, niacin, fibrates, resins, and cholesterol absorption inhibitors. As

We covered the key points on risk stratification and treatment targets from the 2012 CCS guideline on dyslipidemia. We also briefly highlighted cardiovascular age and secondary causes of dyslipidemia. Below are a few useful links: 2012 Update of the Canad

Listen to Tina the pharmacist discuss the 5 first-line antihypertensives: Thiazides ACE Inhibitors Angiotensin Receptor Blockers Beta Blockers Calcium Channel Blockers She lists the mechanism of action, dosing, side effects, drug interactions, and

We looked to the CHEP guidelines again for their recommendations on hypertension treatment thresholds, targets, lifestyle management, pharmacologic treatments, and suggested medications for specific comorbidities. Treatment guidelines on CHEP: http://www.

This is the first episode of the Family Pharm Podcast. In a series of 3 podcasts, we covered one of the most important disease entities in family practice and community pharmacies: hypertension. In episode 1, we focussed on the diagnosis of hypertension,

Hi, my name is Tina Lien, and I am a 4th year pharmacy student at the University of British Columbia. And my name is Billy Lin, a family medicine resident at UBC. Welcome to episode 0 of what we hope to be a long and fruitful adventure, affectionately na